The brief

Analyst view

• Partnerships with Pfizer, Takeda, GSK, and other leading pharma companies validate the platform's utility.
• Boltz integrates open-source structure prediction and binding affinity models with generative AI workflows for drug discovery.
• The platform is used by academic and commercial researchers for protein design and molecular screening.

Technical approach

As reported

Structure prediction

Boltz-1 and Boltz-2 models

Boltz-1 predicts 3D structures with AlphaFold3-level accuracy. Boltz-2 adds binding affinity estimation.

Generative design

BoltzGen molecular design

Generative diffusion models design novel proteins and small molecules.

Integration

Platform and API

Boltz Lab integrates with Benchling, AWS, and OpenAI workflows.